Kratom use and mental health: A systematic literature review and case example

References

• Veltri C, Grundmann O. Current perspectives on the impact of kratom use. Subst Abuse Rehabil. 2019;10:23–31. doi:10.2147/SAR.S164261.
   PubMed Web of Science ®Google Scholar
• Babu KM, McCurdy CR, Boyer EW. Opioid receptors and legal highs: salvia divinorum and kratom. Clin Toxicol. 2008;46(2):146–52. doi:10.1080/15563650701241795.
   PubMed Web of Science ®Google Scholar
• Singh D, Narayanan S, Vicknasingam B, Prozialeck WC, Smith KE, Corazza O, Henningfield JE, Grundmann O. The use of kratom (Mitragyna speciosa Korth.) among people who co-use heroin and methamphetamine in Malaysia. J Addict Med. 2022;16(2):223–8. doi:10.1097/ADM.0000000000000876.
   PubMed Web of Science ®Google Scholar
• Swogger MT, Walsh Z. Kratom use and mental health: a systematic review. Drug Alcohol Depend. 2018;183:134–40. doi:10.1016/j.drugalcdep.2017.10.012.
   PubMed Web of Science ®Google Scholar
• Todd DA, Kellogg JJ, Wallace ED, Khin M, Flores-Bocanegra L, Tanna RS, McIntosh S, Raja HA, Graf TN, Hemby SE, et al. Chemical composition and biological effects of kratom (Mitragyna speciosa): In vitro studies with implications for efficacy and drug interactions. Sci Rep. 2020;10(1):19158. doi:10.1038/s41598-020-76119-w.
   PubMed Web of Science ®Google Scholar
• Grundmann O, Hendrickson RG, Greenberg MI. Kratom: history, pharmacology, current user trends, adverse health effects and potential benefits. Dis Mon. 2023;69(6):101442. doi:10.1016/j.disamonth.2022.101442.
   PubMed Web of Science ®Google Scholar
• Stanciu C, Ahmed S, Gnanasegaram S, Gibson S, Penders T, Grundmann O, McCurdy C. Kratom as an opioid alternative: harm, or harm reduction? A systematic review of literature. Am J Drug Alcohol Abuse. 2022;48(5):509–28. doi:10.1080/00952990.2022.2111685.
   PubMed Web of Science ®Google Scholar
• Tayabali K, Bolzon C, Foster P, Patel J, Kalim MO. Kratom: a dangerous player in the opioid crisis. J Community Hosp Intern Med Perspect. 2018;8(3):107–10. doi:10.1080/20009666.2018.1468693.
   PubMed Web of Science ®Google Scholar
• Drug Enforcement Administration. 2017. Drugs of abuse: a DEA resource guide, Drug Enforcement Administration, US Department of Justice.
   Google Scholar
• FDA. 2018. Statement from FDA Commissioner Scott Gottlieb, M.D., on the Agency’s Scientific Evidence on the Presence of Opioid Compounds in kratom, Underscoring Its Potential for Abuse. U.S. Food and Drug Administration.” In.
   Google Scholar
• Eastlack SC, Cornett EM, Kaye AD. Kratom—Pharmacology, clinical implications, and outlook: a comprehensive review. Pain Ther. 2020;9(1):55–69. doi:10.1007/s40122-020-00151-x.
   PubMed Web of Science ®Google Scholar
• Smith KE, Dunn KE, Rogers JM, Garcia-Romeu A, Strickland JC, Epstein DH. Assessment of kratom use disorder and withdrawal among an online convenience sample of US adults. J Addict Med. 2022;16(6):666–70. doi:10.1097/ADM.0000000000000986.
   PubMed Web of Science ®Google Scholar
• Vento AE, De Persis S, De Filippis S, Schifano F, Napoletano F, Corkery JM, Kotzalidis GD. Case report: treatment of kratom use disorder with a classical tricyclic antidepressant. Front Psychiatry. 2021;12:640218. doi:10.3389/fpsyt.2021.640218.
   PubMed Web of Science ®Google Scholar
• Singh D, Narayanan S, Müller CP, Vicknasingam B, Yücel M, Ho ETW, Hassan Z, Mansor SM. Long-term cognitive effects of kratom (Mitragyna speciosa Korth.) use. J Psychoactive Drugs. 2019;51(1):19–27. doi:10.1080/02791072.2018.1555345.
   PubMed Web of Science ®Google Scholar
• Hassan Z, Muzaimi M, Navaratnam V, Yusoff NHM, Suhaimi FW, Vadivelu R, Vicknasingam BK, Amato D, von Hörsten S, Ismail NIW, et al. From kratom to mitragynine and its derivatives: physiological and behavioural effects related to use, abuse, and addiction. Neurosci Biobehav Rev. 2013;37(2):138–51. doi:10.1016/j.neubiorev.2012.11.012.
   PubMed Web of Science ®Google Scholar
• Sabetghadam A, Ramanathan S, Sasidharan S, Mansor SM. Subchronic exposure to mitragynine, the principal alkaloid of Mitragyna speciosa, in rats. J Ethnopharmacol. 2013;146(3):815–23. doi:10.1016/j.jep.2013.02.008.
   PubMed Web of Science ®Google Scholar
• Assanangkornchai S, Muekthong A, Sam-Angsri N, Pattanasattayawong U. The use of Mitragynine ­speciosa (“Krathom”), an addictive plant, in Thailand. Subst Use Misuse. 2007;42(14):2145–57. doi:10.1080/10826080701205869.
   PubMed Web of Science ®Google Scholar
• Singh D, Müller CP, Vicknasingam BK. Kratom (Mitragyna speciosa) dependence, withdrawal symptoms and craving in regular users. Drug Alcohol Depend. 2014;139:132–7. doi:10.1016/j.drugalcdep.2014.03.017.
   PubMed Web of Science ®Google Scholar
• Nelsen JL, Lapoint J, Hodgman MJ, Aldous KM. Seizure and coma following kratom (Mitragynina speciosa Korth) exposure. J Med Toxicol. 2010;6(4):424–6. doi:10.1007/s13181-010-0079-5.
   PubMedGoogle Scholar
• Castillo A, Payne JD, Nugent K. Posterior reversible leukoencephalopathy syndrome after kratom ingestion. Proc (Bayl Univ Med Cent)). 2017;30(3):355–7. doi:10.1080/08998280.2017.11929647.
   PubMedGoogle Scholar
• LaBryer L, Sharma R, Suresh Chaudhari K, Talsania M, Scofield RH. Kratom, an emerging drug of abuse, raises prolactin and causes secondary hypogonadism: case report. J Investig Med High Impact Case Rep. 2018;6:2324709618765022. doi:10.1177/2324709618765022.
   Web of Science ®Google Scholar
• Sheleg SV, Collins GB. A coincidence of addiction to “kratom” and severe primary hypothyroidism. J Addict Med. 2011;5(4):300–1. doi:10.1097/ADM.0b013e318221fbfa.
   PubMed Web of Science ®Google Scholar
• Lu J, Wei H, Wu J, Jamil MFA, Tan ML, Adenan MI, Wong P, Shim W. Evaluation of the cardiotoxicity of mitragynine and its analogues using human induced pluripotent stem cell-derived cardiomyocytes. PloS One. 2014;9(12):e115648. doi:10.1371/journal.pone.0115648.
   PubMed Web of Science ®Google Scholar
• Chinnappan J, Navari Y, Casini D, Palanisamy N, Parikh N, Seedahmed E. Kratom-induced acute respiratory distress syndrome (ARDS). Eur J Case Rep Intern Med. 2023;10(4):003835. doi:10.12890/2023_003835.
   PubMedGoogle Scholar
• Pantano F, Tittarelli R, Mannocchi G, Zaami S, Ricci S, Giorgetti R, Terranova D, Busardò FP, Marinelli E. Hepatotoxicity induced by “the 3Ks”: kava, kratom and khat. Int J Mol Sci. 2016;17(4):580. doi:10.3390/ijms17040580.
   PubMed Web of Science ®Google Scholar
• Kapp FG, Maurer HH, Auwärter V, Winkelmann M, Hermanns-Clausen M. Intrahepatic cholestasis following abuse of powdered kratom (Mitragyna speciosa). J Med Toxicol. 2011;7(3):227–31. doi:10.1007/s13181-011-0155-5.
   PubMedGoogle Scholar
• Mackay L, Abrahams R. Novel case of maternal and neonatal kratom dependence and withdrawal. Can Fam Physician. 2018;64(2):121–2.
   PubMed Web of Science ®Google Scholar
• Takayama H. Chemistry and pharmacology of analgesic indole alkaloids from the rubiaceous plant, Mitragyna speciosa. Chem Pharm Bull (Tokyo)). 2004;52(8):916–28. doi:10.1248/cpb.52.916.
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Yamamoto LT, Watanabe K, Yano S, Shan J, Pang PK, Ponglux D, Takayama H, Horie S. Inhibitory effect of mitragynine, an analgesic alkaloid from Thai herbal medicine, on neurogenic contraction of the vas deferens. Life Sci. 2005;78(2):187–94. doi:10.1016/j.lfs.2005.04.042.
   PubMed Web of Science ®Google Scholar
• Kruegel AC, Grundmann O. The medicinal chemistry and neuropharmacology of kratom: a preliminary discussion of a promising medicinal plant and analysis of its potential for abuse. Neuropharmacology. 2018;134(Pt A):108–20. doi:10.1016/j.neuropharm.2017.08.026.
   PubMed Web of Science ®Google Scholar
• Prozialeck WC, Jivan JK, Andurkar SV. Pharmacology of kratom: an emerging botanical agent with stimulant, analgesic and opioid-like effects. J Osteopathic Med. 2012;112:792–9.
   Google Scholar
• Johnson LE, Balyan L, Magdalany A, Saeed F, Salinas R, Wallace S, Veltri CA, Swogger MT, Walsh Z, Grundmann O. Focus: plant-based Medicine and Pharmacology: the Potential for kratom as an Antidepressant and Antipsychotic. Yale J Biol Med. 2020;93:283.
   PubMed Web of Science ®Google Scholar
• Raehal KM, Bohn LM. The role of beta-arrestin2 in the severity of antinociceptive tolerance and physical dependence induced by different opioid pain therapeutics. Neuropharmacology. 2011;60(1):58–65. doi:10.1016/j.neuropharm.2010.08.003.
   PubMed Web of Science ®Google Scholar
• Váradi A, Marrone GF, Palmer TC, Narayan A, Szabó MR, Le Rouzic V, Grinnell SG, Subrath JJ, Warner E, Kalra S, et al. Mitragynine/corynantheidine pseudoindoxyls as opioid analgesics with mu agonism and delta antagonism, which do not recruit β-arrestin. J Med Chem. 2016;59(18):8381–97. doi:10.1021/acs.jmedchem.6b00748.
   PubMed Web of Science ®Google Scholar
• Rosenbaum CD, Carreiro SP, Babu KM. Here today, gone tomorrow… and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, Salvia divinorum, methoxetamine, and piperazines. J Med Toxicol. 2012;8(1):15–32. doi:10.1007/s13181-011-0202-2.
   PubMedGoogle Scholar
• Striley CW, Hoeflich CC, Viegas AT, Berkowitz LA, Matthews EG, Akin LP, Iheanyi-Okeahialam C, Mansoor U, McCurdy CR. Health effects associated with kratom (Mitragyna speciosa) and polysubstance use: a narrative review. Subst Abuse. 2022;16:11782218221095873. doi:10.1177/11782218221095873.
   Web of Science ®Google Scholar
• Shellard EJ. The alkaloids of Mitragyna with special reference to those of Mitragyna speciosa, Korth. Bull Narc. 1974;26(2):41–55.
   PubMedGoogle Scholar
• Utar Z, Majid MIA, Adenan MI, Jamil MFA, Lan TM. Mitragynine inhibits the COX-2 mRNA expression and prostaglandin E2 production induced by lipopolysaccharide in RAW264. 7 macrophage cells. J Ethnopharmacol. 2011;136(1):75–82. doi:10.1016/j.jep.2011.04.011.
   PubMed Web of Science ®Google Scholar
• Parthasarathy S, Bin Azizi J, Ramanathan S, Ismail S, Sasidharan S, Said MI, Mansor SM. Evaluation of antioxidant and antibacterial activities of aqueous, methanolic and alkaloid extracts from Mitragyna speciosa (Rubiaceae family) leaves. Molecules. 2009;14(10):3964–74. doi:10.3390/molecules14103964.
   PubMed Web of Science ®Google Scholar
• Bath R, Bucholz T, Buros AF, Singh D, Smith KE, Veltri CA, Grundmann O. Self-reported health diagnoses and demographic correlates with kratom use: results from an online survey. J Addict Med. 2020;14(3):244–52. doi:10.1097/ADM.0000000000000570.
   PubMed Web of Science ®Google Scholar
• Stanciu C, Ahmed S, Hybki B, Penders T, Galbis-Reig D. Pharmacotherapy for management of’kratom use disorder’: a systematic literature review with survey of experts. WMJ. 2021;120(1):54–61.
   PubMedGoogle Scholar
• Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H, Riley D . The CARE Group. The CARE guidelines: consensus-based clinical case reporting guideline development. J Med Case Reports. 2013;7(1):223. doi:10.1186/1752-1947-7-223.
   PubMedGoogle Scholar
• Suwanlert S. A study of kratom eaters in Thailand. Bull Narc. 1975;27(3):21–7.
   PubMedGoogle Scholar
• Prat SS, Rizvi SA, Chaimowitz GA. Kratom-induced Psychosis: case report and literature investigation. Int J Risk Recov. 2020;3(1):29–34. doi:10.15173/ijrr.v3i2.4134.
   Google Scholar
• Cutlip HA, Bushman E, Thottumari L, Mogallapu R, Ang-Rabanes M, Thottumari LE. A case report of kratom-induced psychosis. Cureus. 2021;13(6):e16073. doi:10.7759/cureus.16073.
   PubMed Web of Science ®Google Scholar
• Nunez MB, Dhingra A, Dhingra M, Kossack R, Dhingra M. Kratom’s rising role in the potential exacerbation of mental health disorders: a case report and review of the literature. Psychiatry Res Case Rep. 2022;1(2):100069. doi:10.1016/j.psycr.2022.100069.
   Google Scholar
• Garrels E, Gill G, Mitra S, Korenis P. A case report of kratom-induced psychiatric decompensation. Eur Psychiatr. 2022;65(S1):S826–S826. doi:10.1192/j.eurpsy.2022.2139.
   Google Scholar
• Khalil S, Jabbour F, Karkee A. 2019. A new generation of cyber recreational drugs: a case report on phenibut and kratom induced kidney failure and psychosis. J Hosp Med. 2019;758.
   PubMedGoogle Scholar
• Murad MH, Sultan S, Haffar S, Bazerbachi F. Methodological quality and synthesis of case series and case reports. BMJ Evid Based Med. 2018;23(2):60–3. doi:10.1136/bmjebm-2017-110853.
   PubMedGoogle Scholar
• Abdullah B, Leong MFI. Kratom dependence and treatment options: a comprehensive review of the literature. Curr Drug Targets. 2020;21:1566–79.
   PubMed Web of Science ®Google Scholar
• Kruegel AC, Gassaway MM, Kapoor A, Váradi A, Majumdar S, Filizola M, Javitch JA, Sames D. Synthetic and receptor signaling explorations of the mitragyna alkaloids: mitragynine as an atypical molecular framework for opioid receptor modulators. J Am Chem Soc. 2016;138(21):6754–64. doi:10.1021/jacs.6b00360.
   PubMed Web of Science ®Google Scholar
• Cinosi E, Martinotti G, Simonato P, Singh D, Demetrovics Z, Roman-Urrestarazu A, Bersani FS, Vicknasingam B, Piazzon G, Li J-H, et al. Following “the roots” of kratom (Mitragyna speciosa): the evolution of an enhancer from a traditional use to increase work and productivity in Southeast Asia to a recreational psychoactive drug in western countries. Biomed Res Int. 2015;2015:968786–11. doi:10.1155/2015/968786.
   PubMed Web of Science ®Google Scholar
• Helander A, Rylski A. Drug testing for mitragynine and kratom: analytical challenges and medico-legal considerations. Drug Test Anal. 2023;15(2):213–9. doi:10.1002/dta.3391.
   PubMed Web of Science ®Google Scholar
• Abdullah MFI, Leong Bin D, Singh MT, Swogger AA, Rahim B. Vicknasingam The prevalence of psychotic symptoms in kratom (Mitragyna speciosa Korth.) Users in Malaysia. Asian J Psychiatr. 2019;43:197–201. doi:10.1016/j.ajp.2019.07.008.
   PubMed Web of Science ®Google Scholar
• Weiss ST, Douglas HE. Treatment of kratom withdrawal and dependence with buprenorphine/naloxone: a case series and systematic literature review. J Addict Med. 2021;15(2):167–72. doi:10.1097/ADM.0000000000000721.
   PubMed Web of Science ®Google Scholar
• Hughes RL. Fatal combination of mitragynine and quetiapine–a case report with discussion of a potential herb-drug interaction. Forensic Sci Med Pathol. 2019;15(1):110–3. doi:10.1007/s12024-018-0049-9.
   PubMed Web of Science ®Google Scholar
• Jittasopa W, Srisont S. The causes of death and pathological findings of kratom users: a 5-year retrospective analysis. Am J Forensic Med Pathol. 2021;42(4):335–40. doi:10.1097/PAF.0000000000000691.
   PubMed Web of Science ®Google Scholar
• Grundmann O. Patterns of kratom use and health impact in the US—results from an online survey. Drug Alcohol Depend. 2017;176:63–70. doi:10.1016/j.drugalcdep.2017.03.007.
   PubMed Web of Science ®Google Scholar